A new mouse model to study liver cancer and improve its treatment
A new mouse model for studying the pathogenesis and immunobiology of intrahepatic cholangiocarcinoma and improving its immunotherapy
This study is looking at a tough type of liver cancer called intrahepatic cholangiocarcinoma and is testing a new mouse model to learn more about how the immune system interacts with this cancer, hoping to find better treatment options that work alongside current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10931375 on NIH RePORTER |
What this research studies
This research focuses on intrahepatic cholangiocarcinoma (ICC), a challenging type of liver cancer with a very low survival rate. The team has developed a new mouse model that allows for a better understanding of the immune environment surrounding ICC, which is crucial for developing effective immunotherapies. By studying this model, researchers aim to explore how immune checkpoint inhibitors can be combined with other treatments to enhance their effectiveness against ICC. This approach seeks to address the limitations of current therapies that have not been successful in treating this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with intrahepatic cholangiocarcinoma or those at high risk for developing this type of liver cancer.
Not a fit: Patients with other types of cancers or those who do not have liver-related conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and better survival rates for patients with intrahepatic cholangiocarcinoma.
How similar studies have performed: While there has been significant research on hepatocellular carcinoma, this specific approach to ICC using a new mouse model is relatively novel and has not been extensively tested.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Karin, Michael — University of California, San Diego
- Study coordinator: Karin, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.